[October 16, 2014] |
|
Research and Markets: Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/bkkhsh/ebola_viral)
has announced the addition of the "Ebola
Viral Infections - Pipeline Review, H2 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Ebola Viral Infections, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Ebola Viral Infections and special features on late-stage and
discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Scope
-
The report provides a snapshot of the global therapeutic landscape of
Ebola Viral Infections
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the thrapeutics
development for Ebola Viral Infections and enlists all their major and
minor projects
-
The report summarizes all the dormant and discontinued pipeline
projects
-
A review of the Ebola Viral Infections products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Ebola Viral Infections pipeline on the basis of
target, MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Companies Involved in Therapeutics Development
-
GlaxoSmithKline plc
-
Tekmira Pharmaceuticals Corp.
-
Inovio Pharmaceuticals, Inc.
-
Bavarian Nordic A/S
-
Toyama Chemical Co., Ltd.
-
Crucell N.V.
-
Medicago Inc.
-
NanoViricides, Inc.
-
BioCryst Pharmaceuticals, Inc.
-
Summit Corporation plc
-
AlphaVax, Inc.
-
Chimerix, Inc.
-
Microbiotix, Inc.
-
Immunovaccine, Inc.
-
Integrated BioTherapeutics, Inc.
-
Vaxart, Inc.
-
Profectus BioSciences, Inc.
-
Navigen Pharmaceuticals, Inc.
-
Inhibikase Therapeutics, Inc.
-
Humabs BioMed SA
-
Mapp Biopharmaceutical, Inc.
-
NewLink Genetics Corporation
-
Epirus Biopharmaceuticals, Inc.
Drug Profiles
-
Recombinant Vector Vaccine for Multivalent Filovirus
-
TKM-100802
-
brincidofovir
-
favipiravir
-
Filovirus Vaccine
-
Drugs for Ebola and Marburg Infections
-
SMT-15000
-
panfilovirus vaccine
-
BCX-4430
-
ET-007
-
ZMapp
-
Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses
-
ZMAb
-
MVA-BN-Filoviruses Vaccine
-
ebola virus vaccine
-
ebola and marburg vaccine (trivalent)
-
TKM-100701
-
MMCatLMC
-
ebola and marburg + rabies vaccine
-
Monoclonal Antibodies for Viral Infections
-
imatinib mesylate
-
oxocarbazate
-
thiocarbazate
-
EMER-IT
-
Ebola Vaccine
-
Synthetic Peptides for Ebola Virus
-
Monoclonal Antibodies for Ebola and Marburg Infections
-
ARD-5
-
1-E703
For more information visit http://www.researchandmarkets.com/research/bkkhsh/ebola_viral
[ Back To TMCnet.com's Homepage ]
|